secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0000950170-23-011636
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics closes $287.5M public offering of 19.8M shares at $14.50/share
--------------------------------------------------------------------------------

- Gross proceeds of approximately $287.5 million from 19,828,300 shares at $14.50 per share.
- Underwriters' option to purchase 2,586,300 additional shares exercised in full.
- Net proceeds to fund VK2809, VK2735, VK0214 programs and general corporate purposes.
- William Blair & Co. served as lead book-runner; Raymond James as joint book-runner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023011636/0000950170-23-011636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023011636/vktx-20230403.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer